Virtus Fund Advisers’s ANI Pharmaceuticals ANIP Stock Holding History

Virtus Fund Advisers’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$56.5K	Buy	1,022 +35	+4%	+$2.01K	0.18%	58
2024 Q3	$58.9K	Hold	987	–	–	0.24%	53
2024 Q2	$62.9K	Buy	987 +117	+13%	+$7.6K	0.25%	46
2024 Q1	$60.1K	Hold	870	–	–	0.21%	54
2023 Q4	$48K	Hold	870	–	–	0.3%	50
2023 Q3	$50.5K	Buy	+870	New	+$50.2K	0.36%	44
2017 Q3	–	Sell	-6,188	Closed	-$295K	–	486
2017 Q2	$295K	Sell	6,188 -184	-3%	-$8.88K	﹤0.01%	371
2017 Q1	$315K	Sell	6,372 -411	-6%	-$23.1K	﹤0.01%	377
2016 Q4	$411K	Hold	6,783	–	–	﹤0.01%	356
2016 Q3	$450K	Buy	+6,783	New	+$424K	﹤0.01%	345
2014 Q3	–	Sell	-586	Closed	-$20K	–	1195
2014 Q2	$20K	Buy	+586	New	+$18.4K	﹤0.01%	2432

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtus Fund Advisers's ANIP Position: Q4 2024 in Review

Virtus Fund Advisers increased its ANI Pharmaceuticals (ANIP) stake by 3.5% in Q4 2024, buying an estimated $2.01K and bringing the position to 1,022 shares worth $56.5K. The position accounts for 0.18% of the portfolio, ranked #58.

Virtus Fund Advisers first reported a position in ANIP in Q2 2014 and has held it in 11 quarters since. The position peaked at $450K in Q3 2016. 205 funds tracked by Wall St. Rank hold ANIP as of Q4 2024.

Virtus Fund Advisers held 1,022 shares of ANI Pharmaceuticals worth $56.5K as of Q4 2024.
Virtus Fund Advisers bought 35 ANI Pharmaceuticals shares in Q4 2024, an estimated $2.01K.
ANI Pharmaceuticals made up 0.18% of Virtus Fund Advisers's portfolio in Q4 2024, its #58 holding.
Virtus Fund Advisers first reported a position in ANI Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
Virtus Fund Advisers's ANI Pharmaceuticals position peaked at $450K in Q3 2016.
205 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2024.

Based on Virtus Fund Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.